Skip to main content
. 2011 Oct 5;22(3):382–393. doi: 10.1007/s10165-011-0534-4

Fig. 1.

Fig. 1

Outline of study design. GB-0998 (active drug) was administered to the GB-0998 group in the first period and to the placebo group in the second period. Differences between before and after the 8-week first period in the GB-0998 group were assessed in the primary analysis